Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn

Company News Summary

Mesoblast Completes Enrollment

28 Sep 2017  |  09:50:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: End-Stage Heart Failure Trial Completes Enrollment

Mesoblast announced that a multi-center team of researchers led by Icahn School of Medicine at Mount Sinai Hospital, New York, has completed enrollment of a 159-patient Phase 2b trial evaluating the Company's novel allogeneic mesenchymal precursor cell (MPC) therapy for the treatment of end-stage heart failure. The trial is funded by the US National Institutes of Health (NIH), and the Canadian Institute of Health Research. Due to the serious, life-threatening nature of end-stage heart failure, positive trial results using the Company's product candidate MPC-150-IM in end-stage heart failure patients requiring left ventricular assist devices (LVADs) could provide support for an accelerated regulatory pathway.

Please click here for full details

See more ASX300 News Announcements